PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine

Curr Cancer Drug Targets. 2014;14(4):371-9. doi: 10.2174/1568009614666140403123452.

Abstract

The α(v)β₃ integrin is highly expressed in prostate cancer (PCa), in which it is a key player in tumour invasion, angiogenesis and metastasis formation. Therefore, α(v)β₃ integrin is considered a very promising target for molecular imaging of PCa. This study tested the potential of the novel α(v)β₃ integrin affine agent [⁶⁸Ga]NOTA-RGD in comparison with the established [¹⁸F]fluoroethylcholine (FEC) and [¹⁸F]fluorodeoxyglucose (FDG) for assessing PCa using positron emission tomography (PET). [⁶⁸Ga]NOTA-RGD showed a lower uptake in PC-3 and DU-145 cells compared with FEC and FDG. µPET imaging studies showed a good delineation of the PCa xenografts in mice. The means tumor-to-muscle and tumor-to-bone-ratio amounted 5.1 ± 1.4 and 5.2 ± 1.2 for [⁶⁸Ga]NOTA-RGD compared with 2.6 ± 0.9 and 2.9 ± 1.6 for FDG, and 2.4 ± 0.7 and 0.8 ± 0.2 for FEC, respectively. The uptake of [⁶⁸Ga]NOTA-RGD into tumor was fully inhibited by c(RGDfV), known to bind specifically to α(v)β₃ integrin, confirming the specificity of the tumor uptake in vivo. These results suggest that [⁶⁸Ga]NOTA-RGD is a promising candidate for PET imaging of α(v)β₃ integrin expression in PCa and warrant further in vivo validations to ascertain its potential as an imaging agent for clinical use. The simple and fast preparation of [⁶⁸Ga]NOTA-RGD may greatly facilitate its translation to a clinical setting.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Affinity Labels* / chemistry
  • Affinity Labels* / metabolism
  • Animals
  • Biological Transport / drug effects
  • Cell Line, Tumor
  • Choline / analogs & derivatives
  • Choline / metabolism
  • Coordination Complexes* / antagonists & inhibitors
  • Coordination Complexes* / metabolism
  • Fluorodeoxyglucose F18 / metabolism
  • Gallium Radioisotopes* / chemistry
  • Gallium Radioisotopes* / metabolism
  • Humans
  • Integrin alphaV / chemistry
  • Integrin alphaV / metabolism*
  • Integrin beta3 / chemistry
  • Integrin beta3 / metabolism*
  • Integrins / antagonists & inhibitors
  • Integrins / metabolism
  • Isotope Labeling
  • Male
  • Mice, Nude
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / metabolism
  • Neoplasm Transplantation
  • Oligopeptides* / antagonists & inhibitors
  • Oligopeptides* / metabolism
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacology
  • Positron-Emission Tomography
  • Prostate / diagnostic imaging*
  • Prostate / drug effects
  • Prostate / metabolism
  • Prostate / pathology
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Radiopharmaceuticals / chemistry
  • Radiopharmaceuticals / metabolism

Substances

  • 68Ga-1,4,7-triazacyclononane-1,4-7-triacetic acid-isothiocyanatobenzyl-c(Arg-Gly-Asp-Tyr-Lys)
  • Affinity Labels
  • Coordination Complexes
  • Gallium Radioisotopes
  • Integrin alphaV
  • Integrin beta3
  • Integrins
  • Neoplasm Proteins
  • Oligopeptides
  • Peptides, Cyclic
  • Radiopharmaceuticals
  • cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl)
  • Fluorodeoxyglucose F18
  • fluoroethylcholine
  • Choline